Clinical Trials

Great Falls Clinic Open Research Studies

Learn more about Great Falls Clinic’s Clinical Research Department.

ATB200-02: Phase I/II


Treating: Pompe Disease
Indication: Pompe Disease
Status: Open/Currently Not Enrolling
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-administered With Oral AT2221 in Adult Subjects With Pompe Disease

CAIN457H2315: Phase III


Treating: Axial Spondyloarthritis
Indication: Active non-radiographic Axial Spondyloarthritis
Status: Open and Currently Not Enrolling
A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis

CAIN457K2340: Phase III


Treating: Axial Spondyloarthritis
Indication: Active radiographic Axial Spondyloarthritis
Status: Open and Currently Enrolling
A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active ankylosing spondylitis

CIRT: Cardiovascular Inflammation Reduction Trial


Treating: Cardiac
Status: Open and Not Currently Enrolling
A randomized, double-blind placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of cardiovascular events among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome.

D1699C00001: Phase III


Treating: Heart Failure
Indication: Chronic Heart Failure with Reduced Ejection Fraction
Status: Open/Currently Not Enrolling
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction

DECLARE: Phase IIIb


Treating: Cardiac
Status: Not Currently Enrolling
A multicenter, randomized, double blind, placebo-controlled trial to evaluate the effect of Dapagliflozin 10mg once daily on the incidence of cardiovascular death, myocardial infarction or ischemic stroke in patients with type 2 diabetes.

Meet Our Providers

Russell Herring, DNP

Family Practice

Brandon McCafferty, MD

Ophthalmology

Optical Center

Andrew Lindekugel, DPM

Ambulatory Surgery Center

Podiatry / Podiatric Surgery